SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

12 Aug 2025 Evaluate
The sales is pegged at Rs. 1729.29 millions for the June 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 2444.06 millions during the year-ago period.Profit after Tax for the quarter ended June 2025 saw a decline of -37.48% from Rs. 291.03 millions to Rs. 181.96  millions.Operating profit for the quarter ended June 2025 decreased to 301.08 millions as compared to 410.20 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 1729.29 2444.06 -29.25 1729.29 2444.06 -29.25 9219.26 8193.68 12.52
Other Income 159.30 77.72 104.97 159.30 77.72 104.97 319.29 303.89 5.07
PBIDT 301.08 410.20 -26.60 301.08 410.20 -26.60 1554.60 1410.70 10.20
Interest 32.58 34.73 -6.19 32.58 34.73 -6.19 145.40 163.28 -10.95
PBDT 268.50 375.47 -28.49 268.50 375.47 -28.49 1409.20 1247.42 12.97
Depreciation 86.54 84.44 2.49 86.54 84.44 2.49 344.36 332.19 3.66
PBT 181.96 291.03 -37.48 181.96 291.03 -37.48 1064.84 915.23 16.35
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00
PAT 181.96 291.03 -37.48 181.96 291.03 -37.48 1064.84 947.49 12.39
Equity 507.19 507.19 0.00 507.19 507.19 0.00 507.19 507.19 0.00
PBIDTM(%) 17.41 16.78 3.74 17.41 16.78 3.74 16.86 17.22 -2.06

Orchid Pharma Share Price

544.95 -14.25 (-2.55%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×